For: | Wang MF, Wan B, Wu YL, Huang JF, Zhu YY, Li YB. Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection. World J Gastroenterol 2021; 27(4): 336-344 [PMID: 33584066 DOI: 10.3748/wjg.v27.i4.336] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v27/i4/336.htm |
Number | Citing Articles |
1 |
Haifeng Lv, Yanming Jiang, Geli Zhu, Shiyi Liu, Dian Wang, Jie Wang, Ke Zhao, Jing Liu. Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-28351-3
|
2 |
Laurens A. van Kleef, Hannah S.J. Choi, Willem P. Brouwer, Bettina E. Hansen, Keyur Patel, Robert A. de Man, Harry L.A. Janssen, Robert J. de Knegt, Milan J. Sonneveld. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Reports 2021; 3(5): 100350 doi: 10.1016/j.jhepr.2021.100350
|
3 |
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clinical and Molecular Hepatology 2022; 28(2): 150 doi: 10.3350/cmh.2021.0310
|
4 |
Giovanni Villa, Dorcas Owusu, Colette Smith, Marilyn Azumah, Adam Abdullahi, Suzannah Phillips, Laila Sayeed, Harrison Austin, David Chadwick, Richard Odame Phillips, Anna Maria Geretti. Liver steatosis and fibrosis in people with human immunodeficiency virus in West Africa and the relationship with hepatitis B virus coinfection. Hepatology Communications 2022; 6(11): 3036 doi: 10.1002/hep4.2000
|
5 |
Jiaofeng Huang, Wenjuan Xue, Mingfang Wang, Yinlian Wu, Medha Singh, Yueyong Zhu, Rahul Kumar, Su Lin. MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2021; : 3417 doi: 10.2147/DMSO.S316096
|
6 |
Ke-Gong Xiong, Kun-Yu Ke, Li-Fang Chen, Jin-Feng Kong, Tai-Shun Lin, Qing-Biao Lin, Su Lin, Yue-Yong Zhu. The impact of metabolic dysfunction–associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection. Hepatobiliary & Pancreatic Diseases International 2023; 22(4): 366 doi: 10.1016/j.hbpd.2022.04.001
|
7 |
Kai En Chan, Tiffany Jia Ling Koh, Ansel Shao Pin Tang, Jingxuan Quek, Jie Ning Yong, Phoebe Tay, Darren Jun Hao Tan, Wen Hui Lim, Snow Yunni Lin, Daniel Huang, Mark Chan, Chin Meng Khoo, Nicholas W S Chew, Apichat Kaewdech, Naichaya Chamroonkul, Yock Young Dan, Mazen Noureddin, Mark Muthiah, Mohammed Eslam, Cheng Han Ng. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals. The Journal of Clinical Endocrinology & Metabolism 2022; 107(9): 2691 doi: 10.1210/clinem/dgac321
|
8 |
Yin-Lian Wu, Rahul Kumar, Ming-Fang Wang, Medha Singh, Jiao-Feng Huang, Yue-Yong Zhu, Su Lin. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World Journal of Gastroenterology 2021; 27(34): 5753-5763 doi: 10.3748/wjg.v27.i34.5753
|
9 |
Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name. Clinical and Molecular Hepatology 2022; 28(4): 790 doi: 10.3350/cmh.2022.0070
|
10 |
Yen-Po Lin, Shu-Hsien Lin, Chih-Chi Wang, Chih-Che Lin, Ding-Wei Chen, Ching-Hui Chuang, Pao-Yuan Huang, Chao-Hung Hung, Shih-Yu Yang, Wei-Ru Cho, Yu-Syuan Chen, Ming-Chao Tsai. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection. Journal of Personalized Medicine 2021; 11(8): 684 doi: 10.3390/jpm11080684
|
11 |
Danqing Hu, Peng Wang, Xiaojing Wang, Xue Hu, Da Huang, Weiming Yan, Dong Xi, Meifang Han, Qin Ning, Hongwu Wang. Disease severity and antiviral response in patients with chronic hepatitis B with non-obese NAFLD. Journal of the Formosan Medical Association 2024; 123(7): 773 doi: 10.1016/j.jfma.2023.12.001
|
12 |
Zhao-Chun Chi. Progress in understanding of association between metabolic associated fatty liver disease and viral infectious diseases. World Chinese Journal of Digestology 2022; 30(18): 783 doi: 10.11569/wcjd.v30.i18.783
|
13 |
Shan Hong, Yiwei Hao, Lei Sun, Ping Li, Junru Yang, Fuyang Zhang, Lingling He, Jing Zhang, Hongshan Wei. Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease. Annals of Hepatology 2025; 30(2): 101589 doi: 10.1016/j.aohep.2024.101589
|
14 |
Lin Chen, Xuemei Tao, Minghui Zeng, Yuqin Li, Jiaxin Han, Yuekui Wang, Yonggang Liu, Ruifang Shi, Rui Su, Liang Xu, Yuqiang Mi. Noninvasive tests maintain high accuracy for advanced fibrosis in chronic hepatitis B patients with different nomenclatures of steatotic liver disease. Journal of Medical Virology 2024; 96(4) doi: 10.1002/jmv.29613
|
15 |
Yen-Po Lin, Pei-Ming Wang, Ching-Hui Chuang, Chee-Chen Yong, Yueh-Wei Liu, Pao-Yuan Huang, Chih-Chien Yao, Ming-Chao Tsai. Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.816472
|
16 |
Giovanni Villa, Dorcas Owusu, Marilyn Azumah, Adam Abdullahi, Suzannah Phillips, Laila Sayeed, Harrison Austin, David Chadwick, Richard Odame Phillips, Anna Maria Geretti. Liver Steatosis and Fibrosis in People Living With HIV in West Africa and Relationship With Highly Prevalent Hepatitis B Virus (HBV) Co-Infection. SSRN Electronic Journal 2021; doi: 10.2139/ssrn.3978563
|